Brought to you by:
Rethinking antiplatelet and anticoagulant use in PAD after AQUATIC
During Thursday’s Hot Topics session, John Curci, MD, an associate professor at Vanderbilt Health, discussed the changing landscape of long-term antiplatelet and anticoagulant use in the management of peripheral artery disease (PAD) in light of results from the AQUATIC trial.…
Biomarkers of heart failure show early reversal with catheter thrombolysis compared to anticoagulation alone in a secondary analysis of the SUNSET sPE trial
In a secondary analysis of the SUNSET sPE randomized control trial, lead investigator Efthymios Avgerinos, MD, of the division of vascular surgery, University of Pittsburgh Medical Centre, Pittsburgh, Pennsylvania, and colleagues found differences in biomarker levels in response to treatment…